KKR Real Estate Finance Trust Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw a GAAP loss of $122M and a 13.7% book value decline, driven by asset repositioning and reserve adjustments. Strategic review is underway, with progress on reducing legacy office and watchlist exposures, strong liquidity, and continued share repurchases.
-
Q1 2026 saw a GAAP net loss of $62M and a 9% book value decline as the portfolio transitions, with a focus on resolving legacy office and watchlist assets. Liquidity remains strong at $653M, a $75M buyback program was authorized, and the dividend was cut to $0.10 per share.
-
Attendees were welcomed and the agenda covered three proposals: director elections, auditor ratification, and executive compensation. All proposals passed with a quorum present, and no questions were raised by shareholders.
Fiscal Year 2025
-
Q4 2025 saw a net loss and continued portfolio repositioning, with strong liquidity and capital management. Aggressive asset resolutions and share repurchases aim to unlock value, while market conditions and rate cuts support improved sentiment.
-
Q3 2025 saw $8M GAAP net income and a $0.25 dividend, with book value at $13.78 per share. Liquidity remains strong at $933M, and over $400M in Q4 originations are expected, including the first European loan. REO asset progress and robust market activity support a positive outlook.
-
Reported a GAAP net loss of $35M for Q2 2025, with distributable loss mainly from West Hollywood REO. Originated $211M in new loans, repurchased $20M in shares, and maintained strong liquidity. Portfolio diversification and active pipeline support a positive outlook.
-
Reported a Q1 2025 GAAP net loss of $10.6M, with book value per share at $14.44, down 2%. Origination activity and repayments are strong, leverage is at target levels, and liquidity exceeds $700M. Portfolio growth is expected to be incremental as capital is recycled into new opportunities.
Fiscal Year 2024
-
Q4 2024 saw $14.6M GAAP net income and a flat book value, with distributable loss due to a life science loan write-off. Repayments exceeded $1.5B for the year, watchlist loans declined, and strong liquidity supports optimism for 2025 originations and portfolio growth.
-
Q3 2024 saw a GAAP net loss due to higher CECL reserves, but distributable earnings covered the dividend. Liquidity remains strong, repayments outpaced fundings, and management expects active originations in 2025 as market conditions improve.
-
The discussion highlighted a focus on large transitional loans in institutional real estate, leveraging a diversified platform and strong liquidity. Opportunities are rising as banks pull back, while risk management and capital allocation remain disciplined. M&A and market consolidation are expected in the next 1–2 years.
-
Q2 2024 saw $20.2M GAAP net income and $0.40/share distributable earnings before losses, with book value per share rising to $15.24. Portfolio de-risking continued, liquidity increased, and the company is positioned for new lending as market opportunities grow.